Abstract A026: Deciphering natural and synthetic genetic programs governing human T cell function with combinatorial CRISPR activation and interference screens. Read more about Abstract A026: Deciphering natural and synthetic genetic programs governing human T cell function with combinatorial CRISPR activation and interference screens.
T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation. Read more about T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. Read more about Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways. Read more about PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer. Read more about Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies. Read more about Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies.
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I? Read more about Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?
Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy. Read more about Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy.
Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer. Read more about Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer.
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. Read more about Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
